

Leukemia inhibitory factor regulates marmoset induced pluripotent stem cell proliferation via a PI3K/Akt-dependent Tbx-3 activation pathway

MINXIA KE*, QUAN HE*, DANPING HONG, OUYANG LI, MENGYI ZHU,
WEN-BIN OU, YULONG HE and YUEHONG WU

Department of Biochemistry and Molecular Biology, College of Life Science,
Zhejiang Sci-Tech University, Hangzhou, Zhejiang 310018, P.R. China

Received October 30, 2017; Accepted March 28, 2018

DOI: 10.3892/ijmm.2018.3610

Abstract. Leukemia inhibitory factor (LIF) is the most pleiotropic cytokine of the interleukin-6 family, and is widely used to establish and maintain pluripotent stem cells, particularly mouse pluripotent stem cells. However, no reports have fully elucidated the application of LIF in marmoset induced pluripotent stem cell (iPSC) culture, particularly the underlying mechanisms. To demonstrate the feasibility of the application of LIF to marmoset iPSCs, the present study assessed these cells in the presence of LIF. Cell proliferation was measured using MTT assay, cell apoptosis was determined by flow cytometric analysis of fluorescein isothiocyanate Annexin V staining and the differentially expressed genes were analysed using Digital Gene Expression (DGE) analysis. The altered expression of pluripotency-associated genes was confirmed by reverse transcription-quantitative polymerase chain reaction and western blot analysis. Furthermore, following treatment with LY294002, cell proliferation was measured by MTT assay and protein levels were confirmed by western blot analysis. The results showed that LIF significantly promoted the number of proliferating cells, but had no effect on apoptosis. Digital Gene Expression analysis was used to examine the differentially expressed genes of marmoset iPSCs in the presence of LIF. The results showed that the pluripotency-associated transcription factor-encoding gene T-box 3 (Tbx-3) was activated by LIF. Notably, LIF increased the levels of phosphorylated (p-)AKT and Tbx-3 in the marmoset iPSCs. Furthermore, pretreatment with LY294002, an inhibitor

of phosphoinositide 3-kinase (PI3K), significantly impaired the LIF-induced upregulation of p-AKT and Tbx-3 in the marmoset iPSCs, suggesting that the PI3K/Akt signaling pathway is involved in this regulation. Taken together, the results suggested that LIF is effective in maintaining marmoset iPSCs in cultures, which is associated with the activation of Tbx-3 through regulation of the PI3K/Akt signaling pathway.

Introduction

Induced pluripotent stem cells (iPSCs) provide a promising resource for drug research and the investigation of disease mechanisms and regenerative medicine (1). Nonhuman primates (NHPs) represent an ideal preclinical model for human diseases. Among various NHPs, the marmoset has several unique advantages, including its smaller size, higher rate of breeding, and defined housing conditions, in addition to their relatedness and similar physiology to humans, which makes these animals ideal for developmental research and clinical application (2). Marmoset embryonic stem cell (ESC) lines have previously been established (3-5). According to their requirement of growth factors, including basic fibroblast growth factor (bFGF), for maintaining pluripotency and their molecular signaling pathways for self-renewal, marmoset ESCs are more similar to human ESCs than mouse ESCs (mESCs) (6). To date, marmoset iPSCs have been described in several reports (7-9). In our previous study, it was found that marmoset iPSCs undergo self-renewal and exhibit differentiation similar to that of ESCs (7,10).

Leukemia inhibitory factor (LIF) is a member of the interleukine-6 cytokine family, which utilizes a receptor comprising LIF receptor β and the glycoprotein 130 subunit (11). The functions of LIF, including stimulating or inhibiting proliferation, differentiation, apoptosis and inflammation, are multifaceted, even paradoxical, in different cell types (12-14). Upon LIF stimulation, three intracellular pathways are mainly activated, comprising the Janus kinase (Jak)-signal transducer and activator of transcription (Stat)3, mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)-Akt pathways (15-17). Each of the three pathways has its own critical function in mESCs. Among these pathways, the Jak-Stat3

Correspondence to: Dr Yuehong Wu or Dr Yulong He, Department of Biochemistry and Molecular Biology, College of Life Science, Zhejiang Sci-Tech University, 928 Second Avenue, Hangzhou, Zhejiang 310018, P.R. China
E-mail: wuyuehong2003@163.com
E-mail: heyulong2003@163.com

*Contributed equally

Key words: marmoset, induced pluripotent stem cells, leukemia inhibitory factor, T-box 3, phosphoinositide 3-kinase/AKT

pathway facilitates the self-renewal of mESCs, which are solely regulated by LIF, whereas the PI3K-Akt pathway maintains pluripotency, and the MAPK pathway promotes differentiation, both of which are regulated by multiple pathways (18). Compared with those of mice, human ESCs and iPSCs are primed pluripotent stem cells, which are bFGF-dependent for self-renewal and LIF-independent (19,20). However, the growth factors used in the culture medium of pluripotent stem cells differ among various reports (6,7). Therefore, the most appropriate growth factor and its downstream pathway for maintaining the self-renewal of pluripotent stem cells remains to be elucidated.

In our previous study, it was reported that bFGF was essential and critical for maintaining marmoset iPSCs (7,10). However, whether LIF has an effect in culturing marmoset iPSCs remains to be fully elucidated. Accordingly, in the present study, the functional effects of LIF on the pluripotent state of marmoset iPSCs was investigated. To the best of our knowledge, the present study is the first to apply LIF for the maintenance of marmoset iPSCs. The results of the present study are likely to improve the culture techniques for marmoset iPSCs and facilitate their application as a preclinical experimental resource for human regenerative medicine.

Materials and methods

Cell culture. Marmoset iPSCs were established according to the methods in Dr Peter Hornsby's laboratory (Department of Physiology and The Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San Antonio, TX 78245, USA) and maintained in our laboratory in the Department of Biochemistry and Molecular Biology, College of Life Science, Zhejiang Sci-Tech University (Hangzhou, China). All animal procedures, husbandry and housing were in accordance with the Animal Care and Use Committee requirements of Southwest National Primate Research Center (San Antonio, TX, USA (7)). The cells were cultured in 5% CO₂ with 95% humidity at 37°C in human ESC medium TeSR-E8 (cat. no. 05840; StemCell Technologies, Inc., Vancouver, BC, Canada) supplemented with 10% ESC qualified FBS (cat no. SH30406.02E; Hyclone; GE Healthcare Life Sciences, Logan, UT, USA), 100 U/ml of penicillin, 100 mg/ml of streptomycin (cat. no. 15070-063; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 ng/ml of bFGF (cat. no. F0291; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and 10 μ M Rho-associated kinase (ROCK) inhibitor (Y-27632, cat no. Y0503-1MG, Sigma-Aldrich; Merck KGaA) on Matrigel-coated dishes. The iPSCs were passaged when they reached 80-90% confluency. For passaging, the cells were incubated with Accutase (cat no. 07920, StemCell Technologies, Inc.) to a single-cell mass and replated on Matrigel-coated dishes according to the appropriate split ratio. The medium was replaced daily. To investigate the effect of LIF, the treatment group was supplemented with 1,000 U/ml of mouse LIF (cat no. ESG1106; EMD Millipore), whereas the control cells were cultured in the absence of LIF.

Cell proliferation assay. An MTT assay (Sigma-Aldrich; Merck KGaA) was performed to assess cell proliferation. Briefly, the cells were seeded onto 96-well plates at a density of 5×10^3 . After 24 h, 20 μ l of MTT solution [0.5 mg/ml dissolved in phosphate-buffered saline (PBS)] was added to each test well,

comprising the LIF group, the absence of LIF control group and a blank control group. The cells were then incubated for 3 h at 37°C. The produced formazan precipitate was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich; Merck KGaA). The absorbance was measured at 495 nm using a multi-mode microplate reader. The optical density (OD) values represented the proliferation or the survival of the marmoset iPSCs. Each experiment was repeated three times, followed by calculation of the standard error of the mean.

Flow cytometry. Cell apoptosis was measured according to the manufacturer's protocol with the FITC Annexin V Apoptosis Detection kit (BD Biosciences, Franklin Lakes, NJ, USA). Briefly, the cells were harvested by Accutase, washed twice with PBS and then resuspended in binding buffer. Subsequently, the cells were incubated with Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) for 15 min at 37°C. The samples were analyzed using the FACS Aria system (BD Biosciences). Cell apoptosis was analyzed using FlowJo version 10 software (BD Biosciences).

cDNA library construction, solexa sequencing and digital gene expression (DGE) analysis. The marmoset iPSCs were seeded in a 35-cm² cell culture dish ($\sim 10^4$ cells) and cultured in the presence or absence of LIF (100 U/ml) at 37°C, 5% CO₂ for 24 h. The samples were treated in triplicate. For the DGE analysis (Beijing Genomics Institute, Shenzhen, China), total RNA was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Total RNA was treated with DNase I, and poly-(A) mRNA was enriched with magnetic oligo (dT) beads. The RNA quality and quantity were verified using an Agilent 2100 Bioanalyzer and the ABI StepOnePlus Real-Time PCR system. The mRNA was mixed with fragmentation buffer (10X Fragmentation Reagent, Ambion; Thermo Fisher Scientific, Inc.; cat. no. AM8740) to create short fragments. These were used as templates for first-strand cDNA synthesis with random hexamer primers.

Second-strand cDNA was synthesized according to the manufacturer's protocol using a reaction system of buffer, dNTPs, RNaseH and DNA polymerase I included in the SuperScript® Double-Stranded cDNA Synthesis kit (Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. 11917-010). Short fragments were purified with the QiaQuick PCR extraction kit (Qiagen GmbH, Hilden, Germany; cat. no. 28104) and resolved with EB buffer (Qiagen GmbH; cat. no. 19086) for end reparation and poly (A) addition. These were then connected with adapters and suitable fragments were selected as templates for PCR amplification by using Platinum™ Pfx DNA Polymerase (Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. 11708013), to create the final cDNA library. The following thermocycling conditions were used for the PCR: 94°C for 2 min; 13 cycles of 94°C for 15 sec, 55°C for 30 sec, 68°C for 30 sec; and final extension at 68°C for 5 min. Primer sequences were as follows: Forward, 5-AATGATACG GCGACCACCGAGATCTACTCTTTCCCTACACGA-3; reverse, 5-CAAGCAGAAGACGGCATACGAGAT-3.

The fragments were purified by agarose gel electrophoresis and enriched by PCR amplification. The library products were then ready for solexa sequencing via the Illumina HiSeq 2000 sequencing platform (21), followed by bioinformatics analysis. The transcriptome sequence was assembled into distinct

Table I. Primers used in the present study.

Gene	Sense primer (5'-3')	Antisense primer (5'-3')
β -actin	ATGGAAGAAGAAATTGCTGCG	GCCCATGTAGGAGTCCTTCTG
TBX-3	GAGGCTAAAGAACTTTGGGATC	TGGGCTATCTGGGTGAATG
PI3K	GGCAGCAGTGGAGAGATTTGTT	CCCAAGAATGTGCCCCGAAG
NANOG	ACCTTCCGGTATGGAACAA	CCAAGTCACTGGCAGGAGA
OCT4	AAGGGCAAGCGATCAAGCA	GGGAATGGGACCGAGGAGTA

TBX-3, T-box 3; PI3K, phosphoinositide 3-kinase; OCT4, octamer-binding protein 4.

contigs using the short reads with SOAPdenovo software (version 2.21; <http://soap.genomics.org.cn>). The genome sequence of marmoset was obtained from the National Center for Biotechnology Information (NCBI, www.ncbi.nlm.nih.gov) database. GO term annotation (molecular function, biological process and cellular component) and enrichment analysis was conducted using the Blast2GO software (version 2.2.5) (22).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Total RNA was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. For RT-qPCR analysis, 1 μ g of RNA was used for cDNA synthesis in a reverse transcription reaction using the Prime Script Reagent kit (Takara Bio, Inc., Otsu, Japan). The reaction was incubated at 37°C for 15 min and at 85°C for 5 sec and then amplified by using gene specific primers for qPCR. The qPCR analysis was set up in duplicate with SYBR Premix Ex Taq (Takara Bio, Inc.) and performed using the 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). qPCR reactions of 20 μ l for each sample were made and consisted of cDNA (200 μ g cDNA after dilution), 2X SYBR Premix Ex Taq, 50X ROX Reference Dye, dH₂O and 10 μ M of each gene specific primer. After initial denaturation at 95°C for 30 sec, cDNA was amplified in 40 cycles. Amplification conditions were: 5 sec of denaturation at 95°C, 34 sec of annealing at 60°C and 30 sec of extension at 72°C, followed by a final extension step at 72°C for 10 min. Using the $2^{-\Delta\Delta C_q}$ method (23), the analysis of each sample was repeated three times, and β -actin was used as the house-keeping gene for internal normalization (24). The primers were designed using Primer Premier 5.0 software (Premier Biosoft International, Palo Alto, CA, USA). The sequences of the primers are listed in Table I.

Western blot analysis. The cells were washed twice in PBS, collected, lysed and subsequently boiled in loading buffer at 100°C for 10 min. Protein concentration was determined by the Quick Start Bradford Protein Assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Equal quantities of total protein (20 μ g) were separated on a 12% SDS-PAGE gel at 120 V for 1 h and subsequently blotted onto a nitrocellulose membrane (EMD Millipore) at 100 V for 75 min at 4°C. The membranes were then blocked in 5% nonfat dried milk in PBST [10 mM Tris-HCl (pH 7.5), 150 mM NaCl and 0.1% Tween-20] at room temperature for 1 h according to the antibody manufacturer's protocol. Following a brief wash in PBST (0.1% Tween 20 in PBS), the membranes were incubated with primary antibodies

at 4°C overnight. The primary antibodies included anti- β -actin (cat. no. bs-0061R, BIOSS, Beijing, China), anti-PI3K (85 α) antibody (cat. no. 60225-1-Ig; Full), anti-AKT (cat. no. 9272; Cell Signaling Technology, Danvers, MA, USA), anti-p-AKT (cat. no. 9271; Cell Signaling Technology), anti-STAT3 (cat. no. 10253-2-AP; ProteinTech, Rosemont, IL, USA), anti-Tbx-3 (cat. no. 16741-1-AP; ProteinTech) and anti-NANOG (cat. no. 14295-1-AP; ProteinTech) primary antibodies at a dilution of 1:1,000. The immunoreactive bands were then incubated with the appropriate horseradish peroxidase (HRP)-conjugated secondary anti-rabbit IgG-HRP antibodies (cat. no. A0208; 1:1,000; Beyotime Institute of Biotechnology, Haimen, China), or anti-mouse IgG-HRP antibodies (1:1,000, cat. no. A0216; Beyotime Institute of Biotechnology) for 1 h at room temperature. The protein bands were visualized using enhanced chemiluminescence (ECL) reagent (Amersham; GE Healthcare Life Sciences, Piscataway, NJ, USA) and images were captured by the ECL Tanon 5500 system (Tanon Science and Technology Co., Ltd., Shanghai, China).

PI3K/Akt signaling inhibition. LY294002, a synthetic selective inhibitor of PI3K, was dissolved in DMSO at a concentration of 10 mg/ml based on the manufacturer's protocol. To confirm the involvement of PI3K/Akt signaling on the effects of LIF on marmoset iPSCs, 2x10⁶ cells were treated with the indicated concentration (20 μ M) of LY294002 or an equal volume of DMSO and cultured for 24 h at 37°C. Cell proliferation assays and western blot analysis were then performed, as described above.

Statistical analysis. The data are presented as the mean \pm standard deviation of triplicate experiments (n=3). Student's t-test (two-tailed unpaired) was used to evaluate the significant differences between the control and treated groups. All graphs were plotted using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

LIF induces the proliferation of marmoset iPSCs, but has minimal effect on apoptosis. In the present study, the effects of LIF on maintaining marmoset iPSCs were investigated. First, the morphology and proliferation of marmoset iPSC clones were compared when cultured in media containing different growth factor combinations either in the presence of LIF




Figure 1. Effects of LIF on proliferation of marmoset iPSCs in culture. (A) Morphology and proliferation of marmoset iPSC clones cultured in the presence or absence of LIF for 24 h. The cloning efficiency of marmoset iPSCs was visibly increased in the presence of LIF (scale bar=50 μ m). (B) Cell proliferation was measured using the MTT assay. The cell number in the control group cultured in the absent of LIF, was set as 1.0. *** $P<0.001$ ($n=3$). LIF, leukemia inhibitory factor; iPSCs, induced pluripotent stem cells; bFGF, basic fibroblast growth factor.




Figure 2. Effects of LIF on the apoptosis of marmoset iPSCs in culture. (A) Cell apoptosis was analyzed using flow cytometric analysis of FITC Annexin V staining. FITC Annexin V and PI-positive cells were analyzed by flow cytometry. (B) The majority of marmoset iPSCs were FITC Annexin V and PI negative. Apoptosis in the treatment group was $4.81\pm1.51\%$ and in the control group was $4.25\pm1.01\%$. No significant difference in apoptosis was found. Q1, necrotic cells; Q2, late apoptosis; Q3, early apoptosis; Q4, viable cells; LIF, leukemia inhibitory factor; iPSCs, induced pluripotent stem cells; bFGF, basic fibroblast growth factor.

(LIF+/bFGF+) or in the absence of LIF (LIF-/bFGF+) for 24 h. The morphology of the marmoset iPSCs remained unchanged, whereas the cloning efficiency of the marmoset iPSCs was visibly increased in the presence of LIF (Fig. 1A). To further

characterize the ability of LIF to support the proliferation of marmoset iPSCs, an MTT assay was performed. The results suggested that LIF significantly increased the cell viability ratio, compared with that in the control ($P<0.01$; Fig. 1B).




Figure 3. Differential expression of genes between the LIF-treated and control groups. (A) Sequencing quality assessment in each Digital Gene Expression library. Control-1, marmoset iPSCs cultured in the absence of LIF; Treat-1, marmoset iPSCs cultured in the presence of LIF. Different colors indicate the proportion distribution of reads. The data in parentheses indicate the number and percentage of corresponding tags among the total raw reads. Clean reads represents the raw sequence data without impurity, which is the basis for subsequent information analysis. (B) Venn diagram of the differentially expressed genes shared among the control and treatment groups. There were 15,421 genes shared between the two groups, and 969 and 1,442 genes were independently expressed by the treatment and control groups, respectively. iPSCs, induced pluripotent stem cells; LIF, leukemia inhibitory factor.




Figure 4. Volcano plot for the control and treated datasets. (A) Red indicates the upregulated genes in the LIF-treated group compared with the control group. Green indicates the downregulated genes in the LIF-treated group. (B) Results showing the number of upregulated and downregulated genes between the control and treated datasets. Blue indicates genes without expression differences between the two samples. LIF, leukemia inhibitory factor; DEGs, differentially expressed genes.

Subsequently, the effects of LIF on cell apoptosis were evaluated. To assess cell apoptosis, the samples were subjected to flow cytometric analysis. The results showed that the apoptotic rate in the treatment group was $4.81 \pm 1.51\%$ and that in the control group was $4.25 \pm 1.01\%$. No significant difference was found in the cell apoptotic rate between the treatment group and control group (Fig. 2A and B). These results revealed that the presence of LIF had no effect on apoptosis.

Differentially expressed genes of marmoset iPSCs in the presence or absence of LIF. The present study analyzed the differences between the stages of pluripotency in the presence and absence of LIF through DGE analysis. Two DGE libraries were constructed from the control group and LIF-treated group using Solexa technology. Of the total tags, 99.42 and

99.40% of the tags in each group, respectively, were clean tags, and were used for the analysis (Fig. 3A). The results suggested that the sequences were sufficiently reliable to meet the requirements for the experiment. A total of 15,421 genes were shared between the two groups (Fig. 3B). In the common set of genes, a total of 459 differentially expressed candidate genes were detected between the two groups, among which 151 genes were upregulated and 308 genes were downregulated (Fig. 4A and B). To determine the functions of these differentially expressed genes in inducing proliferation of marmoset iPSCs, a functional enrichment analysis was performed, including all of the differentially expressed pluripotency-associated genes. The 1.0-fold upregulated genes in the samples were defined as significantly differentially expressed genes or regulator genes following the addition of LIF. The analyses indicated that the

Table II. Differentially expressed pluripotency-associated and signaling-related genes in marmoset induced pluripotent stem cells cultured with leukemia inhibitory factor.

Gene	ID	Control-Exp/RPKM	Treat-Exp/RPKM	log2 ratio (treat/control)	P-value	FDR
OCT4	NM_001265584.1	6,712/1,492.90	10,982/2,532.61	0.76	1.13×10^{-263}	2.25×10^{-260}
NANOG	XM_002752302.1	85/22.29	104/28.29	0.34	0.1027	0.2932
TBX-3	XM_002753045.1	0/0.01	1/0.10	3.31	0.4818	0.7507
PI3K (PIK3CG)	XM_002751727.1	61/3.83	185/12.06	1.65	6.68×10^{-17}	3.12×10^{-15}

TBX-3, T-box 3; PI3K, phosphoinositide 3-kinase; OCT4, octamer-binding protein 4.




Figure 5. Altered expression of pluripotency-associated genes confirmed by reverse transcription-quantitative polymerase chain reaction analysis. The results showed the significant upregulation of Tbx-3 and PI3K(85α) ($P < 0.01$). The mRNA level of the control group cultured in the absence of LIF was set as 1. * $P < 0.05$ and *** $P < 0.001$ ($n = 3$). LIF, leukemia inhibitory factor; bFGF, basic fibroblast growth factor; Tbx-3, T-box 3; PI3K, phosphoinositide 3-kinase; Oct-4, octamer-binding protein 4.

expression levels of Tbx-3 and PI3K were significantly higher in the LIF-treated group, compared with those in the control group (Table II). The expression levels of PI3K and Tbx-3 were significantly increased, whereas those of others, including NANOG and SOX2, did not show a significant increase. To confirm the DGE results, RT-qPCR analysis was performed to confirm the expression levels of pluripotency-associated genes. The results showed a marked upregulation in the expression of Tbx-3 and PI3K ($P < 0.01$; Fig. 5), therefore, the results were generally consistent with the DGE data.

LIF-induced upregulation of Tbx-3 is mediated by the PI3K/Akt pathway. As LIF has previously been demonstrated to integrate the Jak/Stat3 and PI3K/Akt signaling pathways to maintain the pluripotency and survival of mESCs (15,16,18,25,26), it is reasonable to hypothesize that one or both of these signaling processes may be key in the activation of pluripotency-associated genes to maintain marmoset iPSCs. To confirm this hypothesis, the cells were treated with or without LIF for 24 h, and the protein levels of STAT3, PI3K, AKT, p-AKT, Tbx-3 and NANOG were assessed by western blot analysis. Compared with the control group, treatment with LIF resulted in a significant increase in the levels of p-AKT and Tbx-3, whereas minimal change in the level of STAT3 was observed

(Fig. 6), suggesting that the LIF-induced upregulation of Tbx-3 was potentially mediated by the PI3K/Akt pathway, but not the Jak/Stat3 pathway.

To confirm the above hypothesis, the present study analyzed marmoset iPSCs cultured in the presence of LY294002, a PI3K inhibitor. The results of the cell proliferation assay demonstrated that inhibition of the PI3K/Akt pathway significantly suppressed cell viability, even in the presence of LIF ($P < 0.01$; Fig. 7A). Additionally, western blot analysis was performed to detect the levels of p-AKT and Tbx-3. The results revealed that the upregulation of p-AKT and Tbx-3 in marmoset iPSCs by LIF was significantly impaired following culture of the marmoset iPSCs in the presence of LY294002 (Fig. 7B). Taken together, these results indicated that LIF promoted the expression of the pluripotency-associated gene Tbx-3 by activating the PI3K/Akt signaling pathway (Fig. 8).

Discussion

Marmosets have been widely recognized as vital, non-human primate models for disease research and preclinical assessment (27). Therefore, marmoset iPSCs offer potential not only for basic mechanism evaluation, but also for therapeutic applications, including regenerative medicine (2). Increasing advances in the field of basic investigations, including the generation of marmoset iPSCs and development of culture conditions, have provided realistic possibilities for human regenerative medicine (7-9). To maintain the self-renewal and pluripotency of marmoset iPSCs *in vitro*, establishment of a simple and effective culture condition, containing a series of cytokines, is significant and urgent. Therefore, the present study investigated the effects of LIF on maintaining marmoset iPSCs, in addition to the underlying mechanisms.

In general, mouse ESCs are naïve pluripotent stem cells, whereas human ESCs are primed pluripotent stem cells, depending on their patterns of gene expression and the cytokines required to maintain self-renewal (19,20,28). An experimental culture of human ESCs requires bFGF supplementation, whereas mESCs are LIF-dependent *in vitro* (29). The application of LIF to establish and maintain marmoset ESCs has long been controversial (3-6). In our previous study, it was found that bFGF is essential and critical for maintaining marmoset iPSCs (7,10). In the present study, the self-renewal ability of marmoset iPSCs in a feeder-free culture was markedly promoted by LIF, in contrast to the characteristic of




Figure 6. Involvement of the PI3K/Akt signaling pathway in LIF-induced activation of Tbx-3 in marmoset induced pluripotent stem cells. The protein expression levels of STAT3, Tbx3, Nanog, p-Akt and PI3K(85α) in the presence or absence of LIF were analyzed by western blot analysis. Actin is shown as a loading control. ***P<0.001 (n=3). LIF, leukemia inhibitory factor; bFGF, basic fibroblast growth factor; STAT3, signal transducer and activator of transcription 3; Tbx-3, T-box 3; PI3K, phosphoinositide 3-kinase; p-, phosphorylated.




Figure 7. LY294002 suppresses cell viability. (A) Cell proliferation was measured using an MTT assay. LY294002, a PI3K inhibitor, reduced the LIF-stimulated proliferation of marmoset induced pluripotent stem cells. The number of cells in the control group cultured without LY294002 was set as 1.0. *P<0.05 and ***P<0.001 (n=3). (B) LIF increased the protein levels of PI3K(85α), p-AKT and TBX-3, and these effects were eradicated by the PI3K inhibitor (LY294002; 20 μM). GAPDH is shown as a loading control. LIF, leukemia inhibitory factor; bFGF, basic fibroblast growth factor; Tbx-3, T-box 3; PI3K, phosphoinositide 3-kinase; p-, phosphorylated.




Figure 8. Model of LIF-mediated expression levels of pluripotency-associated gene by activation of the PI3K/Akt signaling pathway. LIF, leukemia inhibitory factor; PI3K, phosphoinositide 3-kinase; Tbx-3, T-box 3.

human iPSCs (20). Based on the morphology of marmoset iPSCs, it was determined that these cells progressed towards a naïve pluripotency stage in the presence of LIF and that marmoset iPSCs have the potential for differentiation (data not shown).

To clarify the molecular mechanisms by which LIF sustains the self-renewal and pluripotency of marmoset iPSCs, DGE analysis was performed. The results showed that the expression levels of Tbx-3 and PI3K were significantly upregulated. Tbx-3, a known transcriptional repressor, is a member of the T-box transcription factor family and is important in embryonic development and cell fate determination (30,31). Previous studies have demonstrated that the expression of Tbx-3 is associated with the maintenance of pluripotency and self-renewal of ES cells, in addition to the facilitation of reprogramming and establishment of iPSCs (32-36). The present data showed that the effect of LIF on the core circuitry of proliferation and pluripotency in marmoset iPSCs was mediated by the activation of Tbx-3. A previous study showed that the overexpression of Tbx-3 promoted human ES cell proliferation; however, Tbx-3 knockdown resulted in decreased neuroepithelial differentiation (37). Furthermore, the knockdown of Tbx-3 resulted in the loss of pluripotency and differentiation of mESCs (38) and also attenuated the self-renewal ability of mESCs (39), suggesting that Tbx-3 is necessary for maintaining self-renewal ability. Notably, the overexpression of Tbx-3 has been found to be sufficient to maintain mESCs in an undifferentiated state in the absence of LIF (18). The knockdown of Tbx-3 has been shown to prevent extra-embryonic endoderm differentiation, but enhance ectoderm and trophectoderm differentiation (39). It has been reported that the expression of Tbx-3 is downregulated for several days following LIF withdrawal (18,39,40). In addition, the downregulation of Tbx-3 has been shown to attenuate the proliferation of mESCs in the presence of LIF (39).

In mESCs, three LIF signal pathways are involved via different transcription factors (15-17). Briefly, LIF engagement of its receptor results in a cascade of tyrosine

phosphorylation, which stimulates three distinct signaling pathways: The Jak/Stat3 pathway primarily activates Kruppel-like factor 4, whereas the PI3K-Akt and MAPK pathways regulate Tbx-3 (17,18). In marmoset ESCs, Nii *et al* reported that LIF activated the Jak-Stat3 pathway, but did not affect the capacity of self-renewal (6). In the present study, it was identified that LIF activated Tbx-3 through the PI3K-Akt pathway to maintain marmoset iPSC pluripotency and self-renewal. Activation of the PI3K pathway following LIF stimulation was driven by the phosphorylation of the p85 subunit, a regulatory subunit of PI3K, consistent with previous studies (17,41). In addition, the effect of LIF was independent of the Jak-Stat3 pathway. Notably, the DGE data showed a marginal shift in the expression of NANOG and octamer-binding protein 4 (OCT4) in the LIF-treated group, but subsequent validation assessment indicated that the expression levels of NANOG and OCT4 were significantly increased under the same conditions. In the pluripotency network, Tbx-3 interacts with the pluripotency factors NANOG and OCT4 to maintain the stem cell state and inhibit differentiation (42). Niwa *et al* reported that Tbx-3 preferentially activates Nanog and subsequently maintains the expression of Oct3/4 in mESCs (18). In marmoset iPSCs, the expression level of NANOG and OCT4 may be upregulated by the activation of Tbx-3, which requires further investigation.

In conclusion, the present study is the first, to the best of our knowledge, to show that LIF is critical in maintaining the pluripotency and viability of marmoset iPSCs. Furthermore, the effect and mechanism of LIF on marmoset iPSCs was found to involve the activation of pluripotency factor Tbx-3 by the PI3K/Akt signaling pathway. Therefore, the application of LIF provided a simple and effective culture condition for maintaining the self-renewal and pluripotency of marmoset iPSCs.

Acknowledgements

The authors would like to thank Dr Peter Hornsby (Department of Physiology and The Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San Antonio, TX 78245, USA) for kindly providing the marmoset iPS cells.

Funding

This study was supported by the National Natural Science Foundation of China (grant nos. 31201867, 31260287 and 31460585), the Zhejiang Provincial Natural Science Foundation of China (grant no. LY17C120001) and the Science Foundation of Zhejiang Sci-Tech University (grant no. 15042016-Y).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

MK and QH contributed equally to this work. YH and YW conceived and designed the experiments; MK and QH performed the experiments, DH, OL and MZ analyzed

the data; W-BO, YH and YW wrote the paper. All authors approved the final version of the manuscript.

Ethics approval and consent to participate

All animal procedures, husbandry and housing were conducted according to the Animal Care and Use Committee requirements of Southwest National Primate Research Center.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- De Vos J, Bouckenheimer J, Sansac C, Lemaître JM and Assou S: Human induced pluripotent stem cells: A disruptive innovation. *Curr Res Transl Med* 64: 91-96, 2016.
- Wu Y, Mishra A, Qiu Z, Farnsworth S, Tardif SD and Hornsby PJ: Nonhuman primate induced pluripotent stem cells in regenerative medicine. *Stem Cells Int* 2012: 767195, 2012.
- Thomson JA, Kalishman J, Golos TG, Durning M, Harris CP and Hearn JP: Pluripotent cell lines derived from common marmoset (*Callithrix jacchus*) blastocysts. *Biol Reprod* 55: 254-259, 1996.
- Sasaki E, Hanazawa K, Kurita R, Akatsuka A, Yoshizaki T, Ishii H, Tanioka Y, Ohnishi Y, Suemizu H, Sugawara A, *et al*: Establishment of novel embryonic stem cell lines derived from the common marmoset (*Callithrix jacchus*). *Stem Cells* 23: 1304-1313, 2005.
- Müller T, Fleischmann G, Eildermann K, Mätz-Rensing K, Horn PA, Sasaki E and Behr R: A novel embryonic stem cell line derived from the common marmoset monkey (*Callithrix jacchus*) exhibiting germ cell-like characteristics. *Hum Reprod* 24: 1359-1372, 2009.
- Nii T, Marumoto T, Kawano H, Yamaguchi S, Liao J, Okada M, Sasaki E, Miura Y and Tani K: Analysis of essential pathways for self-renewal in common marmoset embryonic stem cells. *FEBS Open Bio* 4: 213-219, 2014.
- Wu Y, Zhang Y, Mishra A, Tardif SD and Hornsby PJ: Generation of induced pluripotent stem cells from newborn marmoset skin fibroblasts. *Stem Cell Res* 4: 180-188, 2010.
- Debowski K, Warthemann R, Lentjes J, Salinas-Riester G, Dressel R, Langenstroth D, Gromoll J, Sasaki E and Behr R: Non-viral generation of marmoset monkey iPS cells by a six-factor-in-one-vector approach. *PloS One* 10: e0118424, 2015.
- Tomioka I, Maeda T, Shimada H, Kawai K, Okada Y, Igarashi H, Oiwa R, Iwasaki T, Aoki M, Kimura T, *et al*: Generating induced pluripotent stem cells from common marmoset (*Callithrix jacchus*) fetal liver cells using defined factors, including Lin28. *Genes Cells* 15: 959-969, 2010.
- Wu Y, Shu J, He C, Li M, Wang Y, Ou W and He Y: ROCK inhibitor Y27632 promotes proliferation and diminishes apoptosis of marmoset induced pluripotent stem cells by suppressing expression and activity of caspase 3. *Theriogenology* 85: 302-314, 2016.
- Cullinan EB, Abbondanzo SJ, Anderson PS, Pollard JW, Lessey BA and Stewart CL: Leukemia inhibitory factor (LIF) and LIF receptor expression in human endometrium suggests a potential autocrine/paracrine function in regulating embryo implantation. *Proc Natl Acad Sci USA* 93: 3115-3120, 1996.
- Mathieu ME, Saucourt C, Mournetas V, Gauthereau X, Thézé N, Praloran V, Thiébaud P and Bœuf H: LIF-dependent signaling: New pieces in the Lego. *Stem Cell Rev* 8: 1-15, 2012.
- McKenzie RC and Szepietowski J: Cutaneous leukemia inhibitory factor and its potential role in the development of skin tumors. *Dermatol Surg* 30: 279-290, 2004.
- Gadient RA and Patterson PH: Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GPI30 transducing receptor: Roles in inflammation and injury. *Stem Cells* 17: 127-137, 1999.
- Zouein FA, Kurdi M and Booz GW: LIF and the heart: Just another brick in the wall? *Eur Cytokine Netw* 24: 11-19, 2013.
- Ohtsuka S, Nakai-Futatsugi Y and Niwa H: LIF signal in mouse embryonic stem cells. *JAKSTAT* 4: e1086520, 2015.
- Nicola NA and Babon JJ: Leukemia inhibitory factor (LIF). *Cytokine Growth Factor Rev* 26: 533-544, 2015.
- Niwa H, Ogawa K, Shimosato D and Adachi K: A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. *Nature* 460: 118-122, 2009.
- Hanna JH, Saha K and Jaenisch R: Pluripotency and cellular reprogramming: Facts, hypotheses, unresolved issues. *Cell* 143: 508-525, 2010.
- Hirai H, Firpo M and Kikyo N: Establishment of LIF-dependent human iPS cells closely related to basic FGF-dependent authentic iPS cells. *PloS One* 7: e39022, 2012.
- Tang LD, Wang XM, Jin FL, Qiu BL, Wu JH and Ren SX: De novo sequencing-based transcriptome and digital gene expression analysis reveals insecticide resistance-relevant genes in *De novo* sequencing-based transcriptome and digital gene expression analysis reveals insecticide resistance-relevant genes in *Propylaea japonica* (Thunberg) (Coleoptea: Coccinellidae) (Thunberg) (Coleoptea: Coccinellidae). *PloS One* 9: e100946, 2014.
- Götz S, García-Gómez JM, Terol J, Williams TD, Nagaraj SH, Nueda MJ, Robles M, Talón M, Dopazo J and Conesa A: High-throughput functional annotation and data mining with the Blast2GO suite. *Nucleic Acids Res* 36: 3420-3435, 2008.
- Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
- Yi F, Yang F, Liu X, Chen H, Ji T, Jiang L, Wang X, Yang Z, Zhang LH, Ding X, *et al*: RNA-seq identified a super-long intergenic transcript functioning in adipogenesis. *RNA Biol* 10: 991-1001, 2013.
- Tan G, Cheng L, Chen T, Yu L and Tan Y: Foxm1 mediates LIF/Stat3-dependent self-renewal in mouse embryonic stem cells and is essential for the generation of induced pluripotent stem cells. *PloS One* 9: e92304, 2014.
- Liu N, Lu M, Feng XM, Ma FX, Fang ZH, Tian XM, Ren Q, Zhang L, Liu B, Huang PP, *et al*: Exogenous Nanog alleviates but is insufficient to reverse embryonic stem cells differentiation induced by PI3K signaling inhibition. *J Cell Biochem* 106: 1041-1047, 2009.
- Saito A: The marmoset as a model for the study of primate parental behavior. *Neurosci Res* 93: 99-109, 2015.
- Buecker C and Geijsen N: Different flavors of pluripotency, molecular mechanisms, and practical implications. *Cell Stem Cell* 7: 559-564, 2010.
- Nichols J and Smith A: Naive and primed pluripotent states. *Cell Stem Cell* 4: 487-492, 2009.
- Govoni KE, Linares GR, Chen ST, Pourteymoor S and Mohan S: T-box 3 negatively regulates osteoblast differentiation by inhibiting expression of osterix and runx2. *J Cell Biochem* 106: 482-490, 2009.
- Dan J, Li M, Yang J, Li J, Okuka M, Ye X and Liu L: Roles for Tbx3 in regulation of two-cell state and telomere elongation in mouse ES cells. *Sci Rep* 3: 3492, 2013.
- Zhao D, Wu Y and Chen K: Tbx3 isoforms are involved in pluripotency maintaining through distinct regulation of Nanog transcriptional activity. *Biochem Biophys Res Commun* 444: 411-414, 2014.
- Willmer T, Peres J, Mowla S, Abrahams A and Prince S: The T-Box factor TBX3 is important in S-phase and is regulated by c-Myc and cyclin A-CDK2. *Cell Cycle* 14: 3173-3183, 2015.
- Willmer T, Hare S, Peres J and Prince S: The T-box transcription factor TBX3 drives proliferation by direct repression of the p21(WAF1) cyclin-dependent kinase inhibitor. *Cell Div* 11: 6, 2016.
- Han J, Yuan P, Yang H, Zhang J, Soh BS, Li P, Lim SL, Cao S, Tay J, Orlov YL, *et al*: Tbx3 improves the germ-line competency of induced pluripotent stem cells. *Nature* 463: 1096-1100, 2010.
- Russell R, Ilg M, Lin Q, Wu G, Lechel A, Bergmann W, Eiseler T, Linta L, Kumar P P, Klingenstein M, *et al*: A dynamic role of TBX3 in the pluripotency circuitry. *Stem Cell Reports* 5: 1155-1170, 2015.

37. Esmailpour T and Huang T: TBX3 promotes human embryonic stem cell proliferation and neuroepithelial differentiation in a differentiation stage-dependent manner. *Stem Cells* 30: 2152-2163, 2012.
38. Ivanova N, Dobrin R, Lu R, Kotenko I, Levorse J, DeCoste C, Schafer X, Lun Y and Lemischka IR: Dissecting self-renewal in stem cells with RNA interference. *Nature* 442: 533-538, 2006.
39. Lu R, Yang A and Jin Y: Dual functions of T-box 3 (Tbx3) in the control of self-renewal and extraembryonic endoderm differentiation in mouse embryonic stem cells. *J Biol Chem* 286: 8425-8436, 2011.
40. Galan-Caridad JM, Harel S, Arenzana TL, Hou ZE, Doetsch FK, Mirny LA and Reizis B: Zfx controls the self-renewal of embryonic and hematopoietic stem cells. *Cell* 129: 345-357, 2007.
41. Storm MP, Kumpfmüller B, Thompson B, Kolde R, Vilo J, Hummel O, Schulz H and Welham MJ: Characterization of the phosphoinositide 3-kinase-dependent transcriptome in murine embryonic stem cells: Identification of novel regulators of pluripotency. *Stem Cells* 27: 764-775, 2009.
42. Lee DF, Su J, Sevilla A, Gengold J, Schaniel C and Lemischka IR: Combining competition assays with genetic complementation strategies to dissect mouse embryonic stem cell self-renewal and pluripotency. *Nat Protoc* 7: 729-748, 2012.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.